메뉴 건너뛰기




Volumn 47, Issue 9, 2009, Pages 587-594

Absolute bioavailability and pharmacokinetics of avosentan in man

Author keywords

Avosentan; Bioavailability; Healthy volunteers; Pharmacokinetics

Indexed keywords

AVOSENTAN; ENDOTHELIN RECEPTOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

EID: 70349916505     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47587     Document Type: Article
Times cited : (3)

References (13)
  • 1
    • 80051499508 scopus 로고    scopus 로고
    • Speedel Pharma Ltd, Basel, Switzerland
    • Speedel Pharma Ltd. Data on file. Basel, Switzerland.
    • Data on file
  • 2
    • 85036781142 scopus 로고    scopus 로고
    • Baltatu OC, Zaugg CE, Bader M, Dembowsky K. Additive kidney protective effects of an angiotensin receptor antagonist combined with the endothelin Type A receptor antagonist SPP301 in rat model of malignant hypertension. Poster presented at the ISH/ESH 2008 in Berlin (abstract # PS13/THU 16/S206). J Hypertension. 2008; 26 (Suppl 1).
    • Baltatu OC, Zaugg CE, Bader M, Dembowsky K. Additive kidney protective effects of an angiotensin receptor antagonist combined with the endothelin Type A receptor antagonist SPP301 in rat model of malignant hypertension. Poster presented at the ISH/ESH 2008 in Berlin (abstract # PS13/THU 16/S206). J Hypertension. 2008; 26 (Suppl 1).
  • 4
    • 52149115147 scopus 로고    scopus 로고
    • Influence of food intake on the pharmacokinetics of avosentan in man
    • Dieterle W, Hengelage T. Influence of food intake on the pharmacokinetics of avosentan in man. Int J of Pharmacology and Therapeutics. 2008; 46: 453-458.
    • (2008) Int J of Pharmacology and Therapeutics , vol.46 , pp. 453-458
    • Dieterle, W.1    Hengelage, T.2
  • 5
    • 0347625574 scopus 로고    scopus 로고
    • A-selective endothelin receptor antagonist SPP301 in healthy human subjects
    • A-selective endothelin receptor antagonist SPP301 in healthy human subjects. J Clin Pharmacol. 2004; 44: 59-66.
    • (2004) J Clin Pharmacol , vol.44 , pp. 59-66
    • Dieterle, W.1    Mann, J.2    Kutz, K.3
  • 8
    • 85036786530 scopus 로고    scopus 로고
    • Jandeleit-Dahm K, Watson A, Soro-Paavonen A, Allen T, Thomas M, Schumacher C, Cooper M. The novel endothelin receptor A (ET-A) antagonist SPP301 attenuated albuminuria and renal structural injury in streptozotocin-induced diabetic apoE knockout mice. Poster presented at the ISH/ESH 2008 in Berlin (abstract # PS12/MON30/S194). J Hypertension. 2008; 26 (Suppl 1).
    • Jandeleit-Dahm K, Watson A, Soro-Paavonen A, Allen T, Thomas M, Schumacher C, Cooper M. The novel endothelin receptor A (ET-A) antagonist SPP301 attenuated albuminuria and renal structural injury in streptozotocin-induced diabetic apoE knockout mice. Poster presented at the ISH/ESH 2008 in Berlin (abstract # PS12/MON30/S194). J Hypertension. 2008; 26 (Suppl 1).
  • 9
    • 0038724606 scopus 로고    scopus 로고
    • Development of a liquid chromatographic/ tandem mass spectrometric assay for a new endothelin receptor antagonist, and its application to dog plasma samples generated after simultaneous i.v. and p.o. administration of the unlabeled and deuterium-labeled forms of this antagonist
    • Lausecker B, Fischer G. Development of a liquid chromatographic/ tandem mass spectrometric assay for a new endothelin receptor antagonist, and its application to dog plasma samples generated after simultaneous i.v. and p.o. administration of the unlabeled and deuterium-labeled forms of this antagonist. J Mass Spectrom. 2003; 38: 649-658.
    • (2003) J Mass Spectrom , vol.38 , pp. 649-658
    • Lausecker, B.1    Fischer, G.2
  • 10
    • 70449454368 scopus 로고
    • Clinical Pharmacokinetics: Concepts and Application. 3rd ed, Lippincott, Williams & Wilkins;
    • Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Application. 3rd ed. Median, PA: Lippincott, Williams & Wilkins; 1995.
    • (1995) Rowland M, Tozer TN
  • 12
    • 85036790971 scopus 로고    scopus 로고
    • A-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. Abstract presented at: 38th American Society of Nephrology Renal Week; Philadelphia; November 8-13, 2005. Abstract 550471.
    • A-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. Abstract presented at: 38th American Society of Nephrology Renal Week; Philadelphia; November 8-13, 2005. Abstract 550471.
  • 13
    • 0023859136 scopus 로고
    • Anovel potent vasoconstrictor peptide produced by vascular endothelial cells
    • Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. Anovel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-415.
    • (1988) Nature , vol.332 , pp. 411-415
    • Yanagisawa, M.1    Kurihara, H.2    Kimura, S.3    Tomobe, Y.4    Kobayashi, M.5    Mitsui, Y.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.